노보렉스
1 known investors
Novorex is a drug discovery company that combines AI, fragment-based drug discovery (FBDD), and biophysical validation (SPR, NMR, X-ray crystallography, and wet-lab assays) to develop novel small-molecule therapeutics. It operates in-house CNS and inflammation pipelines with R&D labs in Pangyo, Central, and Jeongeup.
Investors · 1
Competitors · 4
by search overlapRenovo Rx8 shared keywordsRenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.
Nurix Therapeutics4 shared keywordsNurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
Regenx Biosciences3 shared keywordsREGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.
Seeking Alpha3 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with 노보렉스 for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does 노보렉스 do?
- Novorex is a drug discovery company that combines AI, fragment-based drug discovery (FBDD), and biophysical validation (SPR, NMR, X-ray crystallography, and wet-lab assays) to develop novel small-molecule therapeutics. It operates in-house CNS and inflammation pipelines with R&D labs in Pangyo, Central, and Jeongeup.
- Who are 노보렉스's investors?
- 노보렉스's investors include Solidus Investment.